PD-1 inhibitor combined with radiotherapy and GM-CSF in MSS/pMMR metastatic colon cancer: a case report

Frontiers in Oncology

Oncology

Jiabao Yang¹  Meiling Xu¹  Liyuan Zhang¹  Pengfei Xing¹  Yuehong Kong¹ 

[1]Department of Radiotherapy & Oncology, The Second Affiliated Hospital of Soochow University, Suzhou, China

[2]Institution of Radiotherapy & Oncology, Soochow University, Suzhou, China

[3]Laboratory for Combined Radiotherapy and Immunotherapy of Cancer, The Second Affiliated Hospital of Soochow University, Suzhou, China

关键词: colorectal cancer;    immunotherapy;    radiotherapy;    GM-CSF;    MSS/pMMR;    case report;   

DOI  :  10.3389/fonc.2023.1078915

 received in 2022-10-24, accepted in 2023-04-12,  发布年份 2023

来源: Frontiers

【 摘 要 】

Patients with chemo-refractory metastatic colorectal cancer (mCRC) have poor prognoses. The application of programmed cell death protein 1 (PD-1)/programmed cell death ligand 1 (PD-L1) inhibitors encouragingly improved the survival of mCRC patients with microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR). Unfortunately, it was ineffective for mCRC with microsatellite-stable (MSS)/proficient mismatch repair (pMMR), which accounted for 95% of mCRC. Radiotherapy can promote local control by directly killing tumor cells and inducing positive immune activities, which might help synergistically with immunotherapy. We present the report of an advanced MSS/pMMR mCRC patient who had progressive disease (PD) after first-line chemotherapy, palliative surgery and second-line chemotherapy combined with targeted therapy. Then the patient received the therapy of PD-1 inhibitor combined with radiotherapy and granulocyte-macrophage colony-stimulating factor (GM-CSF). According to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST1.1), the patient showed a complete response (CR) after triple-combined therapy with progression-free survival (PFS) for more than 2 years so far. The patient had no other significant adverse reactions except for fatigue (Grade 1). The triple-combination therapy provided a promising strategy for metastatic chemo-refractory MSS/pMMR mCRC patients.

【 授权许可】

Unknown   
Copyright © 2023 Yang, Xing, Kong, Xu and Zhang